Are Cladribine and Rituximab Enough for the Treatment of Relapsed Hairy Cell Leukemia?

International Journal of Immunotherapy and Cancer Research

Case Report

Are Cladribine and Rituximab Enough for the Treatment of

Relapsed Hairy Cell Leukemia?

Abstract
Introduction: Hairy cell leukemia is a rare B-cell lymph proliferation with long-term survivals, in general. Although therapeutic possibilities have progressed over time, many patients have recurrences and the disease can become resistant to treatment. Discovering the BRAF V600E and other genetic mutations and some pathogenetic mechanisms disruptions open new therapeutic horizons.

http://www.peertechz.com/Immunotherapy-Cancer-Research/pdf/IJICR-1-102.pdf

Comments

Popular posts from this blog

Peertechz is not Predatory Open Access Publisher

The prevention and cure research of emergency intervention therapy of balloon occlusion of LAD occurring reperfusion arrhythmia

Case Report: Reynolds Syndrome